KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities: 2009-2024

Historic Total Non-Current Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 12 years, with Dec 2024 value amounting to $3.8 billion.

  • Alnylam Pharmaceuticals' Total Non-Current Liabilities rose 9.51% to $4.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 9.51%. This contributed to the annual value of $3.8 billion for FY2024, which is 1.01% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Total Non-Current Liabilities of $3.8 billion as of FY2024, which was up 1.01% from $3.7 billion recorded in FY2023.
  • Alnylam Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $3.8 billion during FY2024, with a 5-year trough of $2.4 billion in FY2020.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $3.7 billion (2023), whereas its average is $3.7 billion.
  • Data for Alnylam Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY skyrocketed of 148.43% (in 2020) over the last 5 years.
  • Over the past 5 years, Alnylam Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $2.4 billion in 2020, then increased by 25.64% to $3.0 billion in 2021, then climbed by 18.13% to $3.5 billion in 2022, then increased by 7.16% to $3.7 billion in 2023, then increased by 1.01% to $3.8 billion in 2024.